Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy

NCT04756037 is registered in ClinicalTrials.gov with Sumitomo Pharma Switzerland GmbH as lead sponsor.

NCT NCT04756037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04756037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Phase
Phase 3
Overall status
Completed
Start date
March 18, 2021
Completion date
March 31, 2026
Enrollment
1,164 (actual)
Sites
112

Conditions

As the registry lists them; a condition with its own page is linked.

contraception